Exagen Inc. Amends Filing on Director Changes and Officer Compensation
Ticker: XGN · Form: 8-K/A · Filed: Aug 2, 2024 · CIK: 1274737
| Field | Detail |
|---|---|
| Company | Exagen Inc. (XGN) |
| Form Type | 8-K/A |
| Filed Date | Aug 2, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $460,000, $125,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, leadership-change, executive-compensation
Related Tickers: EXDS
TL;DR
Exagen Inc. amended its filing regarding director changes and officer pay - leadership shuffle incoming.
AI Summary
Exagen Inc. filed an amendment (8-K/A) on August 2, 2024, to a previous filing dated July 31, 2024. The amendment pertains to the departure of a director, the election of a new director, and changes in compensatory arrangements for certain officers. Specific details regarding the individuals involved and the exact nature of the compensatory arrangements are not fully elaborated in the provided text.
Why It Matters
This amendment signals potential shifts in the company's leadership and executive compensation structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Amendments to filings concerning director changes and executive compensation can indicate internal shifts that may carry associated business risks.
Key Numbers
- 001-39049 — SEC File Number (Identifies the specific SEC filing for Exagen Inc.)
- 20-0434866 — IRS Employer Identification No. (Tax identification number for Exagen Inc.)
Key Players & Entities
- EXAGEN INC. (company) — Registrant
- July 31, 2024 (date) — Earliest event date for original report
- August 2, 2024 (date) — Filing date of the amendment
- Delaware (jurisdiction) — State of incorporation
- 1261 Liberty Way Vista, CA 92081 (address) — Principal executive offices
FAQ
What specific event triggered the original 8-K filing on July 31, 2024?
The original 8-K filing on July 31, 2024, was triggered by the departure of a director, the election of a director, and changes in compensatory arrangements for certain officers.
What is the purpose of this 8-K/A filing?
This 8-K/A filing serves as an amendment to a previous report, providing updated or corrected information regarding the events reported on July 31, 2024.
When was this amendment filed with the SEC?
This amendment (8-K/A) was filed with the SEC on August 2, 2024.
What are the main subject matters covered by this amended filing?
The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is Exagen Inc.'s principal executive office address?
Exagen Inc.'s principal executive office is located at 1261 Liberty Way, Vista, CA 92081.
Filing Stats: 1,467 words · 6 min read · ~5 pages · Grade level 10.7 · Accepted 2024-08-02 17:20:36
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share XGN The Nasdaq Global Mar
- $460,000 — be entitled to an annual base salary of $460,000, a signing bonus of $125,000, an annual
- $125,000 — salary of $460,000, a signing bonus of $125,000, an annual target performance bonus of
Filing Documents
- exdx-20240731.htm (8-K/A) — 38KB
- 0001274737-24-000074.txt ( ) — 165KB
- exdx-20240731.xsd (EX-101.SCH) — 2KB
- exdx-20240731_lab.xml (EX-101.LAB) — 22KB
- exdx-20240731_pre.xml (EX-101.PRE) — 13KB
- exdx-20240731_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. The Company issued a press release on August 1, 2024, announcing the executive transition described above. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Employment Agreement by and between the Company and Jeffrey Black (incorporated by reference the Current Report on Form 8-K filed on August 2, 2024). 99.1 Press Release, dated August 1, 2024 (incorporated by reference to the Current Report on Form 8-K filed on August 2, 2024) . 104 Cover Page Interactive Data File (formatted as Inline XBRL) * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 2, 2024 EXAGEN INC. By: /s/ John Aballi Name: John Aballi Title: President and Chief Executive Officer and Interim Chief Financial Officer